{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-261663","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.576801+00:00","generated_at":"2026-05-17T00:51:34.733789+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Karyopharm Q3 net loss $33.1M; XPOVIO revenue up 8.5%; SENTRY data March 2026","bullets":["Total rev $44.0M ($38.8M Q3 2024); U.S. XPOVIO net product rev $32.0M (+8.5% vs $29.5M).","Net loss $33.1M ($3.82/sh) vs $32.1M ($3.85/sh); operating loss improved 42% to $15.2M.","Phase 3 SENTRY myelofibrosis trial enrollment complete (353 pts); top-line data due March 2026.","Reaffirms FY2025 total rev guidance $140M-$155M, XPOVIO rev $110M-$120M; lowers expense guide to $235M-$245M.","Cash $46.2M at Sep 30 (proforma ~$78M after Oct 8 financing); expects liquidity into Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-261663","json":"https://secwatch.observer/filing/0001193125-25-261663.json","markdown":"https://secwatch.observer/filing/0001193125-25-261663.md","text":"https://secwatch.observer/filing/0001193125-25-261663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312525261663/0001193125-25-261663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312525261663/kpti-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:51:34.733789+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}